2024-08-25 - Analysis Report
##  Stock Analysis: ABT (Abbott Laboratories)

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of health care products, including medical devices, pharmaceuticals, and nutrition products. 

**1. Performance vs. S&P 500:**
* **Cumulative Return:** ABT: 56.1%, VOO (S&P 500): 71.75%
* **Lagging behind S&P 500:**  ABT currently lags behind the S&P 500 by 15.65% in cumulative returns. This places it at the 18.89% percentile of historical performance differences, meaning it has outperformed the S&P 500 during a substantial portion of its historical range.

**2. Recent Price Action:**
* **Closing Price:** $112.69
* **5-day Moving Average:** $111.77
* **20-day Moving Average:** $109.54
* **60-day Moving Average:** $105.86
* **Analysis:** ABT is currently trading above its 5, 20, and 60-day moving averages, indicating a bullish trend.

**3. Technical Indicators:**
* **RSI:** 64.84. This indicates ABT is in moderately overbought territory, suggesting potential for a short-term correction.
* **PPO:** 0.16. This positive value suggests potential for further upward momentum.
* **Delta_Previous_Relative_Divergence:** 7.26. The positive value indicates short-term price movement relative to its recent trend. 
* **Analysis:** ABT is showing positive momentum with the PPO and Delta_Previous_Relative_Divergence indicators, but the RSI suggests potential for a short-term correction.

**4. Recent Earnings and Outlook:**
| Date | EPS | Revenue | 
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

* **Analysis:** The most recent earnings report for Q2 2024, released on July 31st, showed EPS of $0.74 and revenue of $10.38 billion. While revenue exceeded analyst expectations, EPS came in below estimates. The company cited a challenging macroeconomic environment and inflation impacting sales. Despite this, ABT's overall financial performance remains strong with consistent revenue growth and a stable dividend payout.

**5. Overall Analysis:**

ABT is a large-cap healthcare company with a strong track record of performance. While it has lagged behind the S&P 500 in recent years, its recent price action and positive technical indicators suggest potential for growth.  The company's consistent earnings and stable dividend payouts make it an attractive investment option for investors seeking long-term growth and income. However, its current RSI suggests a potential short-term correction may occur. 

**6. Recommendations:**

* **For long-term investors:** ABT remains a solid investment option for long-term growth and income.  
* **For short-term investors:**  While current technical indicators show short-term upward momentum, the moderately overbought RSI suggests caution and potential for a short-term correction. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice.  Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
